Immune complex mediated vasculitis

Summary

Immune complex mediated vasculitis (MONDO:0015491) is a disease (an umbrella term covering 5 Mondo subtypes). A subtype of vasculitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 5 Mondo subtypes

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	immune complex mediated vasculitis
Mondo ID	MONDO:0015491
Orphanet	156149
UMLS	C5680655
MedGen	1842565
GARD	0019984
Is cancer (heuristic)	no

Disease family

This is a subtype of vasculitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vasculitis › immune complex mediated vasculitis

Related subtypes (17): choroiditis, Shwartzman phenomenon, central nervous system vasculitis, phlebitis, lymphangitis, aortitis, hypersensitivity vasculitis, retinal vasculitis, vasculitis, lymphocytic, nodular, Kawasaki disease, deficiency of adenosine deaminase 2, secondary vasculitis, cutaneous vasculitis, livedoid vasculopathy, autoimmune vasculitis, arteritis, necrotizing vasculitis

Subtypes (5): Cryoglobulinemic vasculitis, hypocomplementemic urticarial vasculitis, immunoglobulin A vasculitis, cutaneous leukocytoclastic angiitis, erythema elevatum diutinum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.